CJC/IPA (10mg)

The CJC/IPA protocol combines CJC-1295 without DAC (Mod GRF 1-29) and Ipamorelin to amplify pulsatile growth hormone secretion through two independent receptor pathways. CJC-1295 activates GHRH receptors via cAMP/PKA signaling; Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting cortisol or ACTH. Together, they produce synergistic GH spikes that mirror natural physiological pulsatility.

Research Overview

CJC/IPA uses complementary receptor pathways for additive GH release. CJC-1295 without DAC (Mod GRF 1-29) binds GHRH receptors on anterior pituitary somatotrophs, triggering cAMP-mediated GH synthesis. Its short half-life of 30 minutes to 2 hours preserves the pulsatile character of natural GH secretion — important for downstream IGF-1 regulation and receptor sensitivity.

Ipamorelin is a pentapeptide GH secretagogue notable for its receptor selectivity: it activates GHSR1a without stimulating cortisol or ACTH — a key differentiator from earlier GHRPs. The dual-pathway activation produces synergistic GH spikes greater than either peptide achieves independently. Note: this protocol uses the no-DAC version specifically; the DAC version has a 6–8 day half-life and is not interchangeable.

Key Features

• Dual-pathway GH secretagogue combination (5mg CJC-1295 no DAC / 5mg Ipamorelin)
• CJC-1295 (no DAC / Mod GRF 1-29): GHRH receptor agonist; half-life ~30 min–2 hours
• Ipamorelin: Selective ghrelin receptor agonist (GHSR1a); half-life ~2 hours
• Ipamorelin does not affect cortisol, ACTH, or prolactin — highly selective GH release
• Dual-pathway mechanism: cAMP/PKA (CJC) + Gq/11-calcium signaling (Ipamorelin)
• Preserves pulsatile GH release pattern — mimics natural physiological GH secretion rhythm

Common Research Uses

• Commonly studied for pulsatile growth hormone optimization through dual receptor activation
• Researched in relation to lean body mass, muscle protein synthesis, and body composition
• Investigated for fat metabolism and lipolysis under elevated GH/IGF-1 conditions
• Studied in the context of sleep quality and recovery (GH is predominantly secreted nocturnally)
• Researched for anti-aging applications through IGF-1 axis activation

Product Specifications

• Format: Lyophilized powder blend
• Vial size: 5mg/5mg (CJC-1295 no DAC / Ipamorelin)
• Storage: Freeze at −20°C (lyophilized); refrigerate at 2–8°C after reconstitution; use within 28 days

Disclaimer: For research purposes only. Not for human consumption.